ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

DCPH Deciphera Pharmaceuticals Inc

25.45
0.01 (0.04%)
May 15 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 970,463
Bid Price 25.42
Ask Price 25.46
News -
Day High 25.48

Low
9.90

52 Week Range

High
25.55

Day Low 25.44
Company Name Stock Ticker Symbol Market Type
Deciphera Pharmaceuticals Inc DCPH NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.01 0.04% 25.45 18:00:01
Open Price Low Price High Price Close Price Prev Close
25.47 25.44 25.48 25.45 25.44
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
7,110 970,463 $ 25.45 $ 24,700,876 - 9.90 - 25.55
Last Trade Time Type Quantity Stock Price Currency
17:23:52 25 $ 25.46 USD

Deciphera Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
2.06B 80.80M - 163.36M -194.94M -2.41 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Deciphera Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No DCPH Message Board. Create One! See More Posts on DCPH Message Board See More Message Board Posts

Historical DCPH Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week25.3825.5525.3425.402,517,0310.070.28%
1 Month14.9725.5514.0024.824,215,44510.4870.01%
3 Months15.3825.5514.0023.121,763,22810.0765.47%
6 Months12.3025.5511.8120.931,130,48313.15106.91%
1 Year14.0925.559.9018.26838,30611.3680.62%
3 Years34.2538.916.5115.17944,166-8.80-25.69%
5 Years22.6771.116.5123.38759,5302.7812.26%

Deciphera Pharmaceuticals Description

Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.

Your Recent History

Delayed Upgrade Clock